Business context and reporting period
China Pharma Holdings, Inc. filed this Form 10-K for the fiscal year ended December 31, 2015. The company develops, manufactures and sells prescription pharmaceuticals in China through its wholly owned operating subsidiary, Helpson. It reported 20 marketed products and relied on 16 sales offices and more than 1,000 distributors.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $20.35 million | $22.13 million |
| Gross profit and margin | $1.46 million; 7.2% | $2.67 million; 12.1% |
| Operating loss | $14.30 million | $38.76 million |
| Net loss | $15.41 million | $39.55 million |
| Loss per share, basic and diluted | $0.35 | $0.91 |
| Cash from operating activities | $3.35 million | $6.15 million |
| Cash and cash equivalents at year-end | $6.25 million | $5.30 million |
Gross profit includes inventory obsolescence expense of $3.11 million in 2015 and $2.25 million in 2014. Management estimates gross margin excluding that expense at 22.5% and 22.2%, respectively; these are management-adjusted figures, not reported margins.
At year-end, total assets were $97.22 million, current assets $24.96 million and current liabilities $12.79 million. Total liabilities were $24.58 million. Debt included $4.62 million of short-term notes payable and $12.33 million outstanding on the construction loan, of which $1.54 million was current. The company also owed a director $1.35 million under a 1% loan. Cash was held in China and management considered it indefinitely reinvested, limiting availability for payments to the parent or shareholders.
Material changes versus 2014
- Revenue declined 8%, primarily attributed to lost provincial drug tenders following delays in GMP certification, which the company said also affected its market share.
- Net loss narrowed by $24.15 million, largely because bad debt expense fell from $31.35 million to $10.15 million. The 2015 expense included about $4.3 million for advances to suppliers. The company wrote off approximately $21.3 million of previously reserved receivables.
- Gross margin fell to 7.2% from 12.1%, reflecting inventory obsolescence charges and ongoing pricing pressure. Selling expenses rose to $4.29 million from $3.35 million as marketing and sales-collection efforts increased.
- Operating cash flow declined to $3.35 million from $6.15 million. Investing cash outflow eased to $1.90 million from $7.42 million as spending on the new facility and production lines decreased.
- Foreign currency translation reduced comprehensive income by $4.69 million in 2015, compared with $0.65 million in 2014. The prior year also included $2.28 million of typhoon-related losses; there was no comparable expense in 2015.
Outlook, risks and unusual items
- Management said existing resources were expected to fund operations and anticipated capital spending for at least 12 months, but cautioned that weaker-than-planned results could require additional financing or spending reductions. No quantified revenue or earnings guidance was provided.
- The company expected to complete upgrades to its remaining old-factory dry-powder injectable and granule lines in 2016. Production lines that fail to meet GMP requirements could face suspension.
- Pipeline approvals face delays from tighter CFDA review standards and new generic-drug consistency evaluation requirements. The filing says the new rules delayed multiple pipeline applications, but gives inconsistent counts: at least three in one section and at least four in another. No medical formula received production approval in 2015.
- Advances for purchases of intangible assets totaled $42.03 million, a substantial portion of assets. The related formulas remain subject to CFDA approval; the filing reports approximately $4.77 million of further contractual payments over about four years, contingent on milestones.
- Receivables remain a major collection risk: $5.88 million net receivables were reported, while 71.3% of gross receivables were aged over 720 days. One distributor represented 28% of accounts receivable; one supplier represented 27% of raw-material purchases.
- Other risks include Chinese drug-price and tender policies, competition, distributor dependence, currency controls and RMB movements, and reliance on a single manufacturing location. The company reported no material legal proceedings known to it and no off-balance-sheet arrangements.
- Management reported material weaknesses in internal controls over financial reporting concerning inventory-obsolescence estimates and classification/reporting of supplier advances and intangible-asset advances. Management said remediation was underway. The independent auditor expressed an unqualified opinion on the financial statements but did not opine on internal-control effectiveness.
Important facts for investors to verify
- Whether overdue receivables and supplier advances are recoverable, and whether further bad-debt provisions or write-offs are likely.
- Progress and cost of remaining GMP upgrades, and whether the upgraded lines restore tender eligibility and sales.
- CFDA approval status, consistency-evaluation requirements and potential recoverability of the $42.03 million in formula advances.
- Debt repayment capacity and access to the $6.25 million of cash held in China, including the construction-loan repayment schedule.
- Whether internal-control remediation is completed and the company’s estimates and classifications are reliable.